Newsroom

Industry News

11 Sep

Cantabio announces publication of study on a mechanism by which the DJ-1 protein loses its defensive function in neurodegenerative disease conditions

SUNNYVALE, CA–(Marketwired – September 11, 2017) – Cantabio Pharmaceuticals, Inc. (CTBO) (“Cantabio” or the “Company”), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and related neurodegenerative diseases today announced a publication lead authored by Cantabio’s CEO Dr Gergely Tóth, along with collaborators at the...

Read more

8 Sep

PCG Advisory Group Announces Client Availability at the Rodman and Renshaw 19th Annual Global Investment Conference

–14 Clients Available for Investor Introductions–   NEW YORK, NY — 09/8/17 — PCG Advisory Group (PCG), a leading investor relations and integrated communications firm specializing in digital and social media strategies, announced today that 14 clients will be participating in the Rodman & Renshaw 19th Annual Global Investment Conference, New...

Read more

8 Sep

High-Octane Ethanol Blends Can Help Meet GHG Standards

Ethanol organizations presented testimony to the EPA Wednesday that high-octane ethanol blends in optimized engines would be the lowest cost means for the country to meet 2022-2025 fuel economy and greenhouse gas emissions standards. The testimony was provided during a hearing on Reconsideration of the Final Determination of the Midterm Evaluation (MTE) of...

Read more

7 Sep

OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors

Former President and CEO of Advaxis Immunotherapies and Senior Vice President of ImClone Systems adds significant biopharma clinical, regulatory, business development, and fundraising expertise to OncoSec SAN DIEGO, Sept. 7, 2017 /PRNewswire/ — OncoSec Medical Incorporated “OncoSec” (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O’Connor to...

Read more

7 Sep

OncoCyte Receives CLIA Certification for its Cancer Diagnostics Laboratory

ALAMEDA, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that its clinical laboratory facility located in Alameda, California, has received Clinical Laboratory Improvements Amendments (CLIA) certification of registration from the Centers for Medicare...

Read more

7 Sep

BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

TEL AVIV, Israel, September 7, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX)(BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 19th Annual Rodman & Renshaw Global Investment Conference at the...

Read more

6 Sep

Blackboxstocks Announces $5.0 Million Licensing Agreement with EIGH8T Technologies

DALLAS–(BUSINESS WIRE)– Blackboxstocks Inc. (OTC PINK: BLBX) (“Blackbox”), a developer of real-time, web and mobile based analytical software tools for day traders and swing traders, announced today that the Company has signed a two year, $5.0 million licensing agreement with EIGH8T Technologies Inc. (EIGH8T). The agreement provides EIGH8T with exclusive marketing...

Read more

6 Sep

Asterias Biotherapeutics to Present at Upcoming Conferences

FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that members of the Company’s management team will be presenting at two upcoming investor conferences in September: Rodman & Renshaw Annual Global Investment Conference on Monday,...

Read more

6 Sep

Moleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roche’s Drug Avastin

HOUSTON, TX–(Marketwired – September 06, 2017) – Moleculin Biotech, Inc. (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

Page 3 of 25512345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address